The Impact of Diabetes and Metabolic Syndrome Burden on Pain, Neuropathy Severity and Fiber Type
Participants with DPN were more likely to have pain, greater neuropathy severity, and possibly more mixed fiber involvement than those with NDPN. Similarly, increasing MetS burden also led to more painful neuropathy and possibly more severe neuropathy with more mixed fiber involvement.
Authors
- David Martin Simpson (ORCID: https://orcid.org/0000-0001-9072-5088)
- Jo Singleton
- Ahmet Höke (ORCID: https://orcid.org/0000-0003-1215-3373)
- Mazen M. Dimachkie (ORCID: https://orcid.org/0000-0002-7148-989X)
- Stefanie Geisler (ORCID: https://orcid.org/0000-0002-5603-0810)
- Senda Ajroud‐Driss (ORCID: https://orcid.org/0000-0001-7627-425X)
- Brian Christopher Callaghan (ORCID: https://orcid.org/0000-0002-8885-6748)
- Evan Lee Reynolds (ORCID: https://orcid.org/0000-0002-0138-8436)
- A. Gordon Smith
- S.R. Thomas
- Lavanya Muthukumar (ORCID: https://orcid.org/0000-0003-3214-0983)
Institutions
- Northwestern University (US)
- Johns Hopkins University (US)
- Virginia Commonwealth University (US)
- Washington University in St. Louis (US)
- University of Utah (US)
- University of Michigan (US)
- Johns Hopkins Medicine (US)
- University Medical Center (US)
- Mount Sinai Medical Center (US)
- University Hospital and Clinics (US)
- University of Kansas Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1002/acn3.70072
- Citations
- 6
- Primary Topic
- Pain Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.99
Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Johns Hopkins University
- GBS/CIDP Foundation International
- Sarepta Therapeutics
- Amicus Therapeutics
- Myositis Association
- Argenx
- Mitsubishi Tanabe Pharma Corporation
- Grifols
- National Institutes of Health
- Genentech
- Sanofi Genzyme
- Spark Therapeutics
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Neurological Disorders and Stroke